Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brenetafusp + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Immunocore
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Brenetafusp (IMC-F106C) is a novel ImmTAC (Immune mobilizing monoclonal TCRs Against Cancer) bispecific fusion protein that targets PRAME (Preferentially Expressed Antigen in Melanoma) and CD3. It is designed to redirect and activate T cells against PRAME-expressing tumor cells. Pembrolizumab is a humanized monoclonal antibody that blocks the PD-1 receptor on T cells, preventing cancer cells from evading immune detection. The combination of brenetafusp and pembrolizumab aims to enhance anti-tumor immune responses by both directly targeting tumor antigens and releasing immune checkpoint inhibition. This combination has shown promising safety and efficacy in early-phase clinical trials for advanced or metastatic cutaneous melanoma patients who have been previously treated with immune checkpoint inhibitors[2][4][6][8].
- Other names
- IMC-F106CIMC-F-106CIMC-F 106CbrenetafusppembrolizumabKeytruda
02
Targets
CD3 (T-cell surface glycoprotein CD3)PDCD1 (Programmed cell death protein 1 receptor)HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on brenetafusp + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brenetafusp + pembrolizumab.